Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed this Form 8-K on September 14, 2022, to report the entry into a Material Definitive Agreement. The Company is an emerging growth company focused on oncology drug development.
Key Financial Metrics
This filing does not contain periodic financial statements. The only specific financial metric disclosed is the total cost of the new agreement:
- Agreement Cost: $1.5 million for manufacturing and process development services.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The primary material change is the execution of a Manufacturing Agreement with TCG GreenChem, Inc. on September 14, 2022. Key terms include:
- Scope: Manufacture of 25 kg of Ropidoxuridine under cGMP for clinical trial formulation.
- Additional Services: Process research, development, optimization, and creation of working standards for starting materials and intermediates.
- Reporting: TCG GreenChem will provide bi-weekly reports, batch records, and analytical methods.
- Intellectual Property: Shuttle Pharma retains ownership of all IP and improvements developed under the agreement.
Outlook, Risks, and Related Parties
Related Party Transaction: The agreement involves a related party. Dr. Chis Senanayake, an independent director of Shuttle Pharmaceuticals, serves as the CEO and CSO of TCG GreenChem, Inc. and CSO of its parent company, TCG Lifesciences Pvt Ltd.
Outlook: The agreement supports the advancement of Ropidoxuridine and RT for cancer clinical trials.
Risks: The filing notes that certain portions of the agreement exhibit have been redacted due to confidential and proprietary nature, though deemed not material to understanding rights and obligations.
Investor Verification Checklist
- Verify the related party relationship between Dr. Chis Senanayake and TCG GreenChem, Inc.
- Confirm the $1.5 million cost structure and payment terms in the full Exhibit 10.1.
- Assess the impact of the 25 kg manufacturing capacity on the timeline for Ropidoxuridine clinical trials.
- Review the redacted portions of the agreement to ensure no material obligations were omitted from the summary.